Loading...
Market
Story
Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling
Oct 22, 2024, 07:13 PM
Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.
View original story
Similar markets
Sun Pharma • 25%
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Other • 25%
Amjevita • 25%
Wezlana • 25%
Other • 25%
None • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Merck • 25%
Roche • 25%
Another Pharmaceutical Company • 25%
No clear dominator • 25%
Yes • 50%
No • 50%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%